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Abstract. Numerous genetic studies have been conducted 
regarding the occurrence of colorectal cancer (CRC) and the 
prognosis using microarrays. However, adequate investigations 
into the diagnostic application of microarrays have yet to be 
performed. The simplicity and accuracy of diagnosis and prog-
nosis tracking are important requirements for its processes, 
and the use of blood cells for diagnosis is considered to be suit-
able to meet these requirements. The patients involved in the 
study were 28 preoperative patients with CRC and 6 healthy 
individuals who served as controls. RNA was extracted from 
the blood cells of the patients and analyzed using a sense/anti-
sense RNA custom microarray. In the patients with CRC, the 
expression levels of 20 sense RNA and 20 antisense RNA 
species were identified as being significantly altered compared 
with that of the healthy volunteers (P<0.05; fold-change, >2.0). 
Cluster analysis of these RNA species revealed that the top 
10 antisense RNAs significantly clustered patients with cancer 
and healthy individuals separately. Patients with stage I or II 
CRC exhibited significant changes in the expression levels of 
33 sense and 39 antisense RNA species, as compared with 
healthy volunteers (P<0.01; fold-change >2.0). Cluster analysis 
demonstrated that patients with stage I or II CRC and healthy 
volunteers formed separate clusters only among the top 20 
antisense RNA species. A tracking study of expression levels 
of haloacid dehalogenase-like hydrolase domain-containing 1 
(HDHD1) antisense RNA was performed and a significant 
difference was identified between the CRC and healthy 
groups revealing that the levels at one week and three months 
following surgical removal of the cancerous tissue, decreased 
to almost same levels of the healthy individuals. The results of 
the current study indicate that HDHD1 antisense RNA may 
serve as a potential biomarker for the prognosis of CRC.
Introduction
According to the American Cancer Society, colorectal cancer 
(CRC) is currently the third most malignant cancer in the 
United States among males and females (1). In the EU, CRC is 
the second most common cause of cancer-associated mortality 
in males, following lung cancer, and the third most frequent 
cause of cancer-associated mortality in females, following 
breast and lung cancer (2). In Japan, the number of patients 
with CRC has doubled in the past 20 years to become the 
second-leading cause of cancer-associated mortality (3).
CRC is a heterogeneous disease that occurs via a complex 
series of molecular events; a number of genes have previously 
been demonstrated to have a role in the development of the 
healthy mucosa of the large intestine into a benign tumor, 
which then transforms into an invasive cancer (4).
Previous comprehensive studies of >13,000 genes have 
identified 69 genes that are associated with the pathogenesis 
of CRC (4), and detailed analysis has revealed that an average 
of 9 mutant genes are involved in each case of CRC (5). Early 
CRC detection and the monitoring of patient prognosis are 
crucial to improve the survival rates of patients with CRC. 
However, the specimens and array analysis methods reported 
in previous studies have been problematic for the early diag-
nosis and monitoring of prognosis, and are not yet suitable for 
clinical use (4-6).
The development of microarray technology has facilitated 
the high-throughput analysis of numerous gene expression 
patterns (5,6). CRC-specific gene expression profiles have 
been identified in mRNA (5,7-10). Furthermore, the analysis 
of non-coding RNA, including microRNA (miRNA) and anti-
sense RNA, which cannot serve as templates for direct protein 
synthesis, has revealed associations between non-coding 
RNAs and the occurrence of certain types of cancer (11-13). 
Our previous studies demonstrated the potential involvement 
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of antisense RNA expression profiles in the development of 
CRC and hepatic cancer by examining the expression patterns 
of specific RNAs in cancerous and healthy tissues (14,15).
Blood samples are ideal for detection of certain types of 
cancer (12,13) and the monitoring of prognosis; therefore, the 
present study evaluated RNA expression levels in the blood 
cells of patients, in order to determine their effectiveness in 
distinguishing cancerous states and healthy states. The current 
study identified that certain antisense RNA species in blood 
cells cluster separately in patients with CRC and healthy 
volunteers, and revealed that one of these RNA species may 
serve as a biomarker for prognosis.
Materials and methods
Patients and blood samples. Blood samples were collected 
from 6 healthy volunteers and from 28 patients with CRC 
who underwent surgical resection between April 2006 and 
March 2009 at Tsukuba University Hospital (Tsukuba, Japan). 
Blood sampling was periodically conducted up until 12 weeks 
after surgical resection. None of the patients had received 
radiotherapy or chemotherapy prior to surgery. The primary 
clinical characteristics for each patient with CRC involved in 
the current study are presented in Table I. Informed consent 
was obtained from all patients for the collection of blood 
samples and the ethics committee of Tsukuba University 
Hospital approved the study protocol.
Total RNA extraction from blood cells. Blood samples were 
collected from the patients using PAXgene Vacutainer tubes 
(BD Biosciences, Franklin Lakes, NJ, USA) and subjected to 
RNA isolation and extraction using a PAXgene Blood RNA 
Isolation kit (Qiagen, Inc., Valencia, CA, USA), following 
the manufacturer's instructions. The quantity of total RNA 
obtained was determined using a NanoDrop Spectrophotom-
eter (NanoDrop Technologies; Thermo Fisher Scientific, Inc., 
Waltham, MA, USA) according to the 280/260 nm absorbance 
ratio, and RNA integrity was evaluated using an RNA 6000 
Nano LabChip kit (Agilent Technologies, Inc., Santa Clara, 
CA, USA) and an Agilent 2100 Bioanalyzer (Agilent Technolo-
gies, Inc.).
Microarray analysis. Cyanine 3 (Cy3)-labeled cDNA was 
synthesized from 10 µg total RNA extracted from the blood 
samples using a LabelStar Array kit (Qiagen, Inc.) with 
Cy3-dUTP (GE Healthcare Bio-Sciences, Pittsburgh, PA, 
USA) and random nonamer primers. The labeled cDNA 
was hybridized with probe sequences on an Agilent 44 Kx4 
human sense and antisense custom microarray slide (Agilent 
Technologies, Inc.) (16) in a hybridization solution prepared 
with an In Situ Hybridization Plus kit (Agilent Technologies, 
Inc.), according to the manufacturer's instructions. The Cy3 
fluorescence signals were imaged using an Agilent C DNA 
microarray scanner (Agilent Technologies, Inc.) and processed 
using the Feature Extraction version 8.1 software (Agilent 
Technologies, Inc.).
Statistical analysis. The microarray data were processed using 
the GeneSpring GX version 12 software (Agilent Technologies, 
Inc.) to perform the log transformations and the normalization 
of all values to the 75th percentile of the respective microarray, 
followed by normalization to the respective median expression 
level for all samples. Additionally, the normalized gene expres-
sion data were filtered on flags following the protocol of the 
manufacturer GeneSpring GX (http://www.chem.agilent.com/
cag/bsp/products/gsgx/manuals/GeneSpring-manual.pdf). 
Only those genes classified as flag‑present or flag‑marginal in 
>70% of all the array samples, were allowed to pass the filter. 
The expression profiles of the RNA samples were analysed, 
using GeneSpring GX version 12 software, with unpaired 
t-tests, with Benjamini-Hochberg false discovery rate correc-
tion (17) for unequal variances, as described in the results 
section. P<0.05 was considered to indicate a statistically 
significant difference.
Two-dimensional hierarchical clustering based on 
Euclidean distance measures was performed using Ward's 
method (18). The data were visualized using heat maps and 
dendrograms, as described previously (14). Sample trees were 
drawn horizontally and gene trees were drawn vertically. 
Principal component analysis (PCA) was used to identify and 
characterize trends in multigene expression profiles.
Results
RNA quality. The quality of the RNAs obtained from the 
blood samples of the healthy volunteers and patients with CRC 
were initially examined using a NanoDrop Spectrophotometer 
at an absorbance ratio of 280/260 nm, revealing that the ratios 
were between 1.8 and 2.0. These results indicated that the 
total RNAs prepared were usable for labeling with Cy3-dUTP 
and subsequent microarray analysis. The integrity of the 
RNAs was then examined using an Agilent 2100 Bioanalyzer, 
Table I. Clinical characteristics of patients with colorectal 
cancer evaluated using microarray analysis (n=28).
Variable Value
Gender, n  
  Male 21
  Female   7
Median age (range), years 60 (37-86)
Tumor location, n 
  Colon 14
  Rectum 14
AJCC stage, n 
  I   9
  II   9
  III   6
  IV   4
Other samples, n 
  1 week post-surgery samples   4
  3 months post-surgery samples   8
  Volunteers (non-cancer patients)   6
AJCC, American Joint Committee on Cancer.
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revealing that the Rin values of the RNA samples ranged from 
5.9 to 9.2. As the random priming method was utilized for the 
synthesis of Cy3-labeled cDNAs from the RNA samples, the 
lower Rin values were considered not to affect the quality of 
the cDNAs for analysis.
Microarray analysis. Cy3-labeled cDNAs were synthesized 
from the extracted RNA and subjected to microarray anal-
ysis. A total of 40 transcripts were identified as differentially 
expressed with a magnitude of >2-fold (P<0.05) between the 
CRC blood cells and non-cancerous blood cells; of these 
transcripts, 20 were sense sequences and 20 were antisense 
sequences (Table II). According to the cluster analysis, 
CRC and non-cancerous blood samples were revealed to 
form separate clusters for the antisense transcripts, but 
not to form separate clusters for the sense transcripts 
(Fig. 1; the clustering data for the sense transcripts are not 
presented).
Table II. Top 20 antisense transcripts differentially regulated between blood cells from patients with colorectal cancer and healthy 
volunteers.
Accession number Gene symbol Gene name Fold-change
NM_012080 HDHD1 Haloacid dehalogenase-like hydrolase domain-containing 1 5.68
NM_005824 LRRC17 Leucine-rich repeat containing 17 4.38
XR_016125 LOC642337 Similar to hCG1648021 3.40
NM_016630 SPG21 Spastic paraplegia 21 2.71
XM_001132492 LOC732276 Hypothetical protein LOC732276 2.54
NM_175611 GRIK1 Glutamate receptor, ionotropic, kainate 1 2.54
NM_003290 TPM4 Tropomyosin 4 2.40
NM_006516 SLC2A1 Solute carrier family 2, member 1 2.39
NM_015317 PUM2 Pumilio homolog 2 2.36
NM_024494 WNT2B Wingless-type MMTV integration site family, member 2B -2.35
NM_025140 CCDC92 Coiled-coil domain-containing 92 2.31
NM_001037738 NPM1 Nucleophosmin 1 2.31
NM_024860 SETD6 SET domain-containing 6 2.27
NM_020179 SMCO4 Homo sapiens chromosome 11 open reading frame 75 (C11orf75) 2.25
XR_016982 LOC645280 Hypothetical LOC645280 2.21
NM_025225 PNPLA3 Homo sapiens patatin-like phospholipase domain-containing 3 2.20
NM_021975 RELA Homo sapiens v-rel avian reticuloendotheliosis viral oncogene homolog A 2.03
XM_926307 LOC642927 Similar to COLlagen family member (col-36)  2.02
NM_172249 CSF2RA Homo sapiens colony stimulating factor 2 receptor, alpha, low‑affinity  2.02
NM_005206 CPK Homo sapiens v-crk avian sarcoma virus CT10 oncogene homolog  2.00
Figure 1. Hierarchical cluster analysis of the patients with CRC and the healthy volunteers using the top 20 antisense transcripts presented in Table II. Heat 
maps depict color-coded expression levels (the color gradation from red to blue indicates high to low expression levels). CRC, colorectal cancer.
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PCA for 28 patients with CRC using 20 antisense transcripts. 
As presented in Fig. 2, PCA analysis revealed that the CRC 
and non-cancerous blood samples were well separated with 
the first principal component; its contribution rate was ~43.5%. 
The contribution rates of the second and third principal 
components were calculated to be ~7.7% and ~6.4%, respec-
tively. These results indicate that the CRC and non-cancerous 
blood samples were effectively separated with only the first 
component.
Hierarchical cluster analysis of patients with stage I or II 
CRC. The results of the microarray with RNA samples from 
patients with stage I and II CRC and controls revealed a total of 
72 transcripts that were significantly differentially expressed 
Table III. Top 39 antisense transcripts differentially regulated between blood cells from patients with stage I/II colorectal cancer 
and healthy volunteers.
Accession number Gene symbol Gene name Fold-change
XM_001132487.1ea LOC732271 Hypothetical protein LOC732271 6.24
NM_005824.1ea LRRC17 Leucine-rich repeat-containing 17 4.50
NM_012080.3ea HDHD1 Haloacid dehalogenase-like hydrolase domain-containing 1 3.57
NM_024422.2ia DSC2 Desmocollin 2 2.94
NM_174913.1ia NOP9 NOP9 nucleolar protein 2.92
NM_016630.3ia SPG21 Spastic paraplegia 21 2.71
NM_024494.1ia WNT2B Wingless-type MMTV integration site family, member 2B 2.61
NM_175611.2ea GRIK1 Glutamate receptor, ionotropic, kainate 1 2.54
NM_014578.2ia RHOD Ras homolog family member D 2.54
NM_006296.3ia VRK2 Vaccinia-related kinase 2 2.47
NM_139284.1ia LGI4 Leucine-rich repeat LGI family 2.44
NM_001315.1ia MAPK14 Mitogen-activated protein kinase 14 2.40
XR_016125.1ea LOC642337 Similar to hCG1648021 2.39
NM_005618.2ia DLL1 Felta-like 1 (Drosophila) 2.37
XM_001132492.1ea LOC732276 Hypothetical protein LOC732276 2.36
NM_025225.2ia PNPLA3 Patatin-like phospholipase domain-containing 3 2.31
NM_171846.1ea LACTB Lactamase, β 2.31
NR_002162.1ea ATP5EP2 Synthase, H+ transporting, mitochondrial F1 complex, epsilon 2.29
  subunit pseudogene 2
XM_001125928.1ea LOC283804 Similar to testicular metalloprotease-like, disintegrin-like,  2.25
  Cysteine-rich protein Iva
XM_001129971.1ea LOC729333 Hypothetical protein LOC729333 2.23
NM_212554.2ia METTL10 Methyltransferase-like 10 2.22
NM_006516.1ia SLC2A1 Solute carrier family 2, member 1 2.20
NM_015317.1ia PUM2 Pumilio homolog 2 2.18
XM_293121.4ea C20orf66 Chromosome 20 open reading frame 66  2.15
NM_003290.1ia TPM4 Tropomyosin 4 2.12
XR_016982.1ea LOC645280 Hypothetical LOC645280 2.12
XR_018204.1ea LOC647757 Similar to tetratricopeptide repeat protein 4 (TPR repeat protein 4)  2.09
NM_006708.1ia GLO1 Glyoxalase I 2.08
NM_020179.1ia SMCO4 Single-pass membrane protein with coiled-coil domains 4  2.06
NM_001010898.1ia SLC6A17 Solute carrier family 6 (neutral amino acid transporter), member 17  2.06
NM_004423.3ia DVL3 Dishevelled segment polarity protein 3 2.05
NM_001093.2ia ACACB Acetyl-CoA carboxylase β 2.04
NM_005751.3ia AKAP9 A kinase (PRKA) anchor protein 9 2.04
NM_025140.1ia CCDC92 Coiled-coil domain-containing 92 2.04
NM_017440.2ia MDM1 Mdm1 nuclear protein homolog (mouse)  2.04
NM_000637.2ia GSR Glutathione reductase 2.03
NM_080588.1ia PTPN7 Protein tyrosine phosphatase, non-receptor type 7 2.02
NM_024860.1ia SETD6 SET domain-containing 6 2.01
NM_005206.3ia CRK V-crk avian sarcoma virus CT10 oncogene homolog 2.01
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with a magnitude of >2-fold (P<0.01) between the blood cells 
of healthy volunteers and of patients with CRC. A total of 
33 transcripts were sense sequences and 39 were antisense 
sequences (Table III). When the blood samples from patients 
with stage I or II CRC and healthy volunteers were subjected 
to cluster analysis for the aforementioned sense and antisense 
transcripts, the patients were observed to form respective clus-
ters only with antisense transcripts (Fig. 3; the clustering data 
for the sense transcripts are not presented).
PCA with stage I or II CRC using 39 antisense transcripts. 
The 39 antisense transcripts were further examined using PCA 
analysis. As presented in Fig. 4, CRC and non-cancerous RNA 
samples were revealed to be well separated with regard to the 
first principal component; its contribution rate was ~43.5%. 
The contribution rates of the second and third principal 
components were calculated to be ~7.9% and ~7.0%, respec-
tively. These results indicate that the patients with stage I or II 
CRC were effectively separated from healthy volunteers with 
the first component.
Comparison of HDHD1 antisense transcript expression 
levels. The antisense transcript of haloacid dehalogenase-like 
hydrolase 1 domain-containing (HDHD1), which was the 
highest and third highest differentially expressed transcript 
in the earlier analyses (Tables II and III, respectively), was 
Figure 2. Principal component analysis for 28 patients with CRC and 6 
healthy volunteers using the 20 antisense transcripts presented in Table II. 
The data are representative of the top three components; the contribution 
ratios of components 1, 2 and 3 were 43.5, 7.7 and 6.4%, respectively. CRC, 
colorectal cancer.
Figure 3. Hierarchical cluster analysis of patients with stage I or II CRC 
and healthy volunteers, using the top 39 antisense transcripts presented in 
Table III. Heat maps depict color-coded expression levels (the color gradation 
from red to blue indicates high to low expression levels). CRC, colorectal 
cancer.
Figure 4. Principal component analysis for 18 patients with stage I or II 
CRC and 6 healthy volunteers using the 39 antisense transcripts presented in 
Table III. The data are representative of the top 3 components; the contribu-
tion ratios of components 1, 2 and 3 were 43.5, 7.9 and 7.0%, respectively. 
CRC, colorectal cancer.
Figure 5. Comparison of haloacid dehalogenase-like hydrolase 
domain-containing 1 antisense transcript expression levels in the blood cell 
samples of healthy volunteers and patients with CRC prior to surgery and at 
one week and three months after surgery. CRC, colorectal cancer.
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selected for evaluation at various time points following 
the surgical resection of tumor tissues from patients with 
CRC. The expression levels of the HDHD1 antisense 
transcript at 1 week and at 3 months post-surgery were 
decreased approximately to the expression levels 
observed in healthy volunteers (Fig. 5). The results suggest 
that certain antisense transcripts, including HDHD1, 
may serve as potential biomarkers of CRC diagnosis 
and prognosis.
Discussion
Previous studies have identified the potential involvement of 
antisense RNA expression in the development of colorectal 
and hepatic cancers by examining RNA expression patterns 
in cancerous and healthy tissues (14,15). However, the func-
tions and underlying mechanisms of antisense transcripts in 
colorectal and hepatic cancers have yet to be elucidated. The 
present study examined the association between the expres-
sion levels of certain RNA transcripts in blood cells and the 
occurrence of CRC, and the subsequent changes in the tran-
script amount following the removal of cancerous tissues in 
patients. The examinations revealed that antisense transcripts 
of up to 39 genes demonstrated a clear association between 
their expression levels in blood cells and the occurrence of 
CRC; following tumor resection in patients with CRC, the 
expression levels of the HDHD1 antisense transcript were 
decreased to approximately the levels observed in healthy 
volunteers, suggesting that these antisense transcripts 
are involved in the generation and maintenance of CRC. 
Furthermore, the antisense transcripts may serve as diag-
nostic markers for CRC occurrence, and certain antisense 
transcripts, including HDHD1, may be potential prognostic 
markers for CRC.
The early detection of CRC significantly improves patient 
prognosis and is essential in reducing CRC-associated 
mortality (19) Patients with CRC often present with an 
advanced stage disease and concomitant poor prognosis (1). 
The best known serum biomarkers, carcinoembryonic 
antigen (CEA) and carbohydrate antigen 19-9 (CA19-9), are 
not recommended for clinical screening due to limited speci-
ficity and sensitivity (20). A number of circulating proteins 
have previously been indicated to be diagnostically useful; 
however, none of these proteins has individually demonstrated 
sufficient sensitivity or specificity to be used in clinical prac-
tice (20).
In our previous study, the expression levels of certain anti-
sense transcripts in CRC tissues were revealed to significantly 
differ from their corresponding normal tissues (14), indicating 
that those specific antisense transcripts may be involved in 
the generation and maintenance of CRC tumor tissues. The 
antisense transcripts in CRC tissues are distinct from those 
identified in the present study of patients with CRC. Further 
studies are required to determine the functional association 
between the antisense transcripts revealed in our previous 
study and those in the present study.
Previous studies have indicated that certain antisense 
transcripts are involved in mRNA stabilization (21), the 
suppression of mRNA synthesis (22,23), miRNA func-
tions (24) and the promotion of protein synthesis (25). 
Therefore, antisense transcripts have various functions, each 
of which may be specific to the respective antisense transcript 
species. Although the functions of non-coding RNA, antisense 
RNA and miRNA in tumorigenesis require further study, it 
is possible that the various antisense transcripts demonstrated 
in the present study may serve as potential biomarkers for 
CRC diagnosis and prognosis. In the future, the mechanisms 
underlying the differences in expression levels of the antisense 
transcripts should be investigated extensively to understand 
their involvement in CRC generation.
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